Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Graft vs Host Disease 1

Interventions

pembrolizumab 1024Carboplatin 966Paclitaxel 933Gemcitabine 794Cisplatin 753Docetaxel 684Bevacizumab 609Pemetrexed 504Nivolumab 487Cyclophosphamide 474Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 373Oxaliplatin 348Injections 347atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 246Doxorubicin 241Ipilimumab 226fludarabine 220Lenalidomide 220Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × eritoran × Clear all
NCT00756912 2014-07-11

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Eisai Inc.

Phase 1 Terminated
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡